$ISRG

Jeddi Iman sold $2.4M of ISRG

Jeddi Iman (SVP & GM da Vinci Platforms &) sold 5,625 shares of INTUITIVE SURGICAL INC (ISRG) at $420.55 ($2.37M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jeddi Iman
Published Jun 2, 2026, 2:08 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 2:10 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ISRG
Neutral
medium confidence
Mentioned
$ISRG
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

Because the sale is pre-arranged, it is generally treated as lower-signal for company-specific negative news; the main tradable element is short-term sentiment/positioning.

02

Market read

A disclosed insider sale in ISRG, but with 10b5-1 framing, suggesting limited fundamental implications.

03

What to watch

Check whether this sale is part of a larger sequence of officer sales or whether other insiders are buying/selling around the same window.

Relevance 6/10Novelty 6/10Timing: Filed June 2; sale executed June 1

Background

The filing is an SEC Form 4 for an officer (SVP & GM da Vinci Platforms) reporting an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Intuitive Surgical disclosed an officer open-market sale of 5,625 shares under a pre-arranged 10b5-1 plan on June 1.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless follow-on selling accelerates.

Evidence & confidence

The transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Minimal; single-company 10b5-1 sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution about near-term execution or valuation.

Key entities

  • Intuitive Surgical

    Subject of the Form 4 insider transaction disclosure.

  • Jeddi Iman

    Officer reporting the sale of ISRG shares.

  • Rule 10b5-1 plan

    Pre-arranged trading plan that reduces discretionary interpretation.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGMedAI 8/10

Intuitive Surgical Vs. Stryker: Wall Street Loves Both But One Has a Quiet Advantage That Will Make Investors Money

Intuitive Surgical (ISRG) and Stryker (SYK) both reported strong Q2 2026 earnings, with ISRG highlighting 85% recurring revenue and SYK showing 9.4% revenue growth. ISRG's da Vinci systems and SYK's MedSurg and Neurotechnology segments drove performance. ISRG's CEO noted portfolio strength, while SYK's CEO cited regained momentum. Analysts favor ISRG for its compounding moat and recurring revenue model, with 25 EPS revisions in 30 days.

$ISRGMedAI 8/10

New da Vinci Surgical Robot Secures Marketing Approval: Entering Olympus’ Core Dominant Surgical Market

Intuitive Surgical received FDA approval for its flexible gastrointestinal robot, IG1000, marking its entry into a market dominated by Olympus. The company plans to refine the product before commercial launch, focusing on clinical benefits and user experience. Analysts note the product's force feedback and suturing capabilities, highlighting Intuitive's strategic expansion beyond its da Vinci surgical robots.

$NKELow

Can These Beaten Down Stocks Bounce Back?

NIKE (NKE) and Intuitive Surgical (ISRG) shares have underperformed in 2026. NIKE reported Q4 adjusted EPS of $0.20, beating estimates, but revenue declined 1%. ISRG's Q2 adjusted EPS rose 27.9%, topping estimates, with revenue up 18.5%. Both face challenges, with NIKE struggling with sales declines and ISRG dealing with valuation concerns and slower procedure growth.

$ABTMed

Abbott vs. Intuitive Surgical: Which MedTech Stock Offers Better Long-Term Upside?

Abbott Laboratories (NYSE:ABT) and Intuitive Surgical (NASDAQ:ISRG) reported strong quarterly results, with Abbott raising its annual profit outlook and Intuitive beating revenue and earnings expectations. Abbott's diversification across diagnostics, medical devices, and nutrition drove growth, while Intuitive's robotic surgery ecosystem and recurring revenue model supported its performance. Despite the positive results, Intuitive's shares declined due to slowing domestic procedure growth. Abbot

$DHRMedAI 8/10

Danaher vs. Intuitive Surgical: Is Recovery or Innovation the Better Long-Term Bet?

Danaher (DHR) and Intuitive Surgical (ISRG) present contrasting growth paths. Danaher benefits from improving life sciences spending, with strong bioprocessing orders and $100M revenue shifted to next year. Intuitive Surgical reports 18% YoY growth in da Vinci system placements, 70% non-GAAP gross margin, and 85% recurring revenue. Investors must decide between cyclical recovery and structural growth.